Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1-and HIV-2-infected individuals from Senegal, West Africa

被引:112
作者
Gottlieb, GS
Sow, PS
Hawes, SE
Ndoye, L
Redman, M
Coll-Seek, AM
Faye-Niang, MA
Diop, A
Kuypers, JM
Critchlow, CW
Respess, R
Mullins, JI
Kiviat, NB
机构
[1] Univ Washington, HPV Res Grp, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98103 USA
[2] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98103 USA
[3] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98103 USA
[4] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98103 USA
[5] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98103 USA
[6] Roche Mol Diagnost, Alameda, CA USA
[7] Univ Dakar, Dept Infect Dis, Dakar, Senegal
[8] Inst Publ Hlth, Dakar, Senegal
关键词
D O I
10.1086/339295
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human immunodeficiency virus (HIV) type 2 infection is characterized by slower disease progression to acquired immunodeficiency syndrome than results from HIV-1 infection. To better understand the biological factors underlying the different natural histories of infection with these 2 retroviruses, we examined the relationship between HIV RNA and DNA levels and the rate of CD4(+)T cell decline among 472 HIV-1- and 114 HIV-2-infected individuals from Senegal. The annual rate of CD4(+) T cell decline in the HIV-2 cohort was approximately one-fourth that seen In the HIV-1 cohort. However, when the analysis was adjusted for baseline plasma HIV RNA level, the rates of CD4(+)T cell decline per year for the HIV-1 and HIV-2 cohorts were similar (a rate increase of similar to4% per year for each increase in viral load of 1 log(10) copies/mL). Therefore, plasma HIV load is predictive of the rate of CD4(+) T cell decline over time, and the correlation between viral load and the rate of decline appears to be similar among all HIV-infected individuals, regardless of whether they harbor HIV-1 or HIV-2.
引用
收藏
页码:905 / 914
页数:10
相关论文
共 44 条
[1]  
ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P1482
[2]   Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa -: Significantly, lower plasma virus set point in HIV-2 infection than in HIV-1 infection [J].
Andersson, S ;
Norrgren, H ;
da Silva, Z ;
Biague, A ;
Bamba, S ;
Kwok, S ;
Christopherson, C ;
Biberfeld, G ;
Albert, J .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (21) :3286-3293
[3]  
[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221
[4]   A community-based study of human immunodeficiency virus type 2 provirus load in a rural village in West Africa [J].
Ariyoshi, K ;
Berry, N ;
Wilkins, A ;
Ricard, D ;
Aaby, P ;
Naucler, A ;
Ngom, PT ;
Jobe, O ;
Jaffar, S ;
Dias, F ;
Tedder, RS ;
Whittle, H .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :245-248
[5]   Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa [J].
Ariyoshi, K ;
Jaffar, S ;
Alabi, AS ;
Berry, N ;
van der Loeff, MS ;
Sabally, S ;
N'Gom, PT ;
Corrah, T ;
Tedder, R ;
Whittle, H .
AIDS, 2000, 14 (04) :339-344
[6]  
Berry N, 1998, J Hum Virol, V1, P457
[7]   HIV TYPE-2 PROVIRAL LOAD MEASURED BY QUANTITATIVE POLYMERASE CHAIN-REACTION CORRELATES WITH CD4+ LYMPHOPENIA IN HIV TYPE 2-INFECTED INDIVIDUALS [J].
BERRY, N ;
ARIYOSHI, K ;
JOBE, O ;
NGUM, PT ;
CORRAH, T ;
WILKINS, A ;
WHITTLE, H ;
TEDDER, R .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (08) :1031-1037
[8]   PROVIRUS COPY NUMBER TO PREDICT DISEASE PROGRESSION IN ASYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
CHEVRET, S ;
KIRSTETTER, M ;
MARIOTTI, M ;
LEFRERE, F ;
FROTTIER, J ;
LEFRERE, JJ .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (04) :882-885
[9]   PCR-based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells [J].
Christopherson, C ;
Kidane, Y ;
Conway, B ;
Krowka, J ;
Sheppard, H ;
Kwok, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (02) :630-634
[10]  
Christopherson C, 1998, ANTIVIR THER, V3, P247